



Exploring Metabolomics and Other Biomarkers for Osteosarcopenic Adiposity Detection, Prevention and Management

Guest Editor:

Prof. Dr. Jasminka Ilich-Ernst

Institute for Successful Longevity,
Florida State University,
Tallahassee, FL 32306, USA

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

The purpose of this Special Issue is to bring more insight into the metabolic nature of OSA by investigating the following:

1. Biomarkers for each tissue (bone, muscle, adipose) which, in combination, may indicate the existing impairments and presence of OSA, possibly discovering/identifying or proposing the series of omics.
2. In view of recent technological advances, such as genomic sequencing and molecular targeted drug exploitation, the concept of precision medicine can be used to demarcate OSA using multiple data sources from genomics to digital health metrics to artificial intelligence in order to facilitate an individualized yet “evidence-based” decisions regarding diagnostic and therapeutic approaches. In this way, therapeutics can be centered toward patients based on their molecular presentation rather than grouping them into broad categories with a “one size fits all” approach.
3. Any type of review or research article is welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy
2. Formerly Professor of Internal Medicine, School of Specialization of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Biochemistry & Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

Contact Us

Metabolites Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/metabolites
metabolites@mdpi.com
X@MetabolitesMDPI